[go: up one dir, main page]

MX2009005604A - Spiroketone acetyl-coa carboxylase inhibitors. - Google Patents

Spiroketone acetyl-coa carboxylase inhibitors.

Info

Publication number
MX2009005604A
MX2009005604A MX2009005604A MX2009005604A MX2009005604A MX 2009005604 A MX2009005604 A MX 2009005604A MX 2009005604 A MX2009005604 A MX 2009005604A MX 2009005604 A MX2009005604 A MX 2009005604A MX 2009005604 A MX2009005604 A MX 2009005604A
Authority
MX
Mexico
Prior art keywords
sup
spiroketone
acetyl
coa carboxylase
carboxylase inhibitors
Prior art date
Application number
MX2009005604A
Other languages
Spanish (es)
Inventor
Jeffrey Wayne Corbett
Andrew Simon Bell
Richard Louis Elliott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2009005604A publication Critical patent/MX2009005604A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> and R<sup>9</sup> are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.
MX2009005604A 2006-11-29 2007-11-16 Spiroketone acetyl-coa carboxylase inhibitors. MX2009005604A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86177906P 2006-11-29 2006-11-29
PCT/IB2007/003639 WO2008065508A1 (en) 2006-11-29 2007-11-16 Spiroketone acetyl-coa carboxylase inhibitors

Publications (1)

Publication Number Publication Date
MX2009005604A true MX2009005604A (en) 2009-06-08

Family

ID=39126209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005604A MX2009005604A (en) 2006-11-29 2007-11-16 Spiroketone acetyl-coa carboxylase inhibitors.

Country Status (23)

Country Link
US (1) US20090270435A1 (en)
EP (1) EP2097420B1 (en)
JP (1) JP2010511035A (en)
KR (1) KR20090083956A (en)
CN (1) CN101541809A (en)
AP (1) AP2009004880A0 (en)
AT (1) ATE552262T1 (en)
AU (1) AU2007326950B2 (en)
BR (1) BRPI0721053A2 (en)
CA (1) CA2670422C (en)
CO (1) CO6180424A2 (en)
CR (1) CR10831A (en)
EA (1) EA200900613A1 (en)
EC (1) ECSP099371A (en)
IL (1) IL198779A0 (en)
MA (1) MA30932B1 (en)
MX (1) MX2009005604A (en)
NO (1) NO20091889L (en)
RS (1) RS20090249A (en)
SV (1) SV2009003281A (en)
TN (1) TN2009000204A1 (en)
WO (1) WO2008065508A1 (en)
ZA (1) ZA200903268B (en)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081559A1 (en) * 2007-01-12 2008-11-20 Merck & Co Inc SPIROCHROMANONE DERIVATIVES SUBSTITUTED AS ACETYL COA CARBOXYLASE INHIBITORS
JP5271917B2 (en) * 2007-01-12 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Spirochromanone derivatives
CN100550853C (en) * 2007-01-25 2009-10-14 华为技术有限公司 A flow control implementation method and device based on an output queue
DE102007028521A1 (en) * 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
ES2545231T3 (en) 2008-05-28 2015-09-09 Pfizer Inc. Pyrazoloespirocetone acetyl-CoA carboxylase inhibitors
JP2011521940A (en) * 2008-05-28 2011-07-28 ファイザー・インク Pyrazolospiroketone acetyl CoA carboxylase inhibitor
WO2010002010A1 (en) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Novel spirochromanone carboxylic acids
US8110570B2 (en) 2008-07-14 2012-02-07 Cropsolution, Inc. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof
DE102008038222A1 (en) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carboxylic acid derivatives
EP2184276A1 (en) 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
EP2947082A1 (en) * 2009-11-10 2015-11-25 Pfizer Inc N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
WO2011058473A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2792234C (en) 2010-03-19 2014-05-27 Pfizer Inc. 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro [3.5] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
HUE031616T2 (en) 2010-09-30 2017-07-28 Pfizer N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
AU2011322117B2 (en) 2010-10-29 2015-01-22 Pfizer Inc. N1/N2-lactam acetyl-CoA carboxylase inhibitors
PT2670752E (en) 2011-02-02 2016-06-14 Vertex Pharma Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
CA2827311A1 (en) * 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
CA2829803A1 (en) 2011-03-14 2012-09-20 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
GEP20166474B (en) 2011-04-22 2016-05-10 Pfizer Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
CN103702978B (en) 2011-07-08 2018-03-06 拜耳知识产权有限责任公司 Process for the preparation of 2-amino-5-cyano-N,3-dimethylbenzamide
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
BR112014000288A2 (en) 2011-07-22 2017-01-10 Pfizer quinolinyl glucagon receptor modulators
ES2561105T3 (en) 2011-08-18 2016-02-24 Nippon Shinyaku Co., Ltd. Heterocyclic derivative as a microsomal prostaglandin E synthase inhibitor (mPGES)
JP6043355B2 (en) 2011-08-31 2016-12-14 ファイザー・インク Hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compound
BR112014011254A2 (en) 2011-11-11 2017-05-16 Pfizer 2-thiopyrimidinones
SG11201405477XA (en) 2012-04-06 2014-11-27 Pfizer Diacylglycerol acyltransferase 2 inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2852597B1 (en) 2012-05-04 2016-06-08 Pfizer Inc Heterocyclic substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of app, bace1 and bace 2.
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
ES2665153T3 (en) 2013-10-09 2018-04-24 Pfizer Inc. Prostaglandin EP3 receptor antagonists
PE20161368A1 (en) 2014-03-17 2016-12-25 Pfizer DIACILGLICEROL ACILTRANFERASE 2 INHIBITORS
ME03599B (en) 2014-04-04 2020-07-20 Pfizer Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
CR20160455A (en) 2014-04-10 2016-12-16 Pfizer 2-AMINO-6-METHYL-4,4a, 5,6-TETRAHYDROPIRANE [3,4-d] [1,3] TIAZIN-8a (8H) -IL-1,3-TIAZOL-4-ILA
WO2016092413A1 (en) 2014-12-10 2016-06-16 Pfizer Inc. Indole and indazole compounds that activate ampk
JP2017538769A (en) 2014-12-22 2017-12-28 ファイザー・インク Prostaglandin EP3 receptor antagonist
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
WO2016193844A1 (en) 2015-05-29 2016-12-08 Pfizer Inc. Novel heterocyclic compounds as inhibitors of vanin-1 enzyme
CR20170572A (en) 2015-06-17 2018-03-20 Pfizer TRICYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2017025849A1 (en) 2015-08-13 2017-02-16 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds
AU2016311376B2 (en) 2015-08-27 2018-10-04 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators
WO2017037567A1 (en) 2015-09-03 2017-03-09 Pfizer Inc. Regulators of frataxin
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
WO2017051276A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
ES2871251T3 (en) 2015-12-29 2021-10-28 Pfizer 3-Azabicyclo [3.1.0] Substituted Hexanes as Ketohexokinase Inhibitors
CA3030381A1 (en) 2016-07-14 2018-01-18 Pfizer Inc. Pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (en) 2016-08-19 2018-11-07 Pfizer DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS
WO2019133445A1 (en) 2017-12-28 2019-07-04 Inception Ibd, Inc. Aminothiazoles as inhibitors of vanin-1
CN108658938B (en) * 2018-06-15 2021-03-23 上海现代制药股份有限公司 A kind of synthetic method of dabigatran etexilate mesylate process impurity
CN108774242B (en) * 2018-08-22 2020-10-27 牡丹江医学院 Medicine for preventing and treating coronary heart disease and preparation method thereof
MX2021002428A (en) 2018-08-31 2023-01-02 Pfizer COMBINATIONS FOR THE TREATMENT OF NASH/ANFG AND RELATED DISEASES.
CN109400618B (en) * 2018-11-09 2021-08-10 中国药科大学 Chroman derivative and preparation method and application thereof
WO2020102575A1 (en) 2018-11-16 2020-05-22 Inception Ibd, Inc. Heterocyclic aminothiazoles and uses thereof
CN109809992A (en) * 2019-02-16 2019-05-28 安徽华胜医药科技有限公司 Synthesis method of 2- (2-fluoro-3-methoxyphenyl) -2-ethyl glycolate
ES3039586T3 (en) 2019-05-20 2025-10-22 Pfizer Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN110128347A (en) * 2019-06-17 2019-08-16 韶远科技（上海)有限公司 A kind of synthetic method of 1-methyl-1H-indazole-6-carboxylic acid
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
MA58498B1 (en) 2020-02-07 2024-08-30 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
CN114437096B (en) * 2020-11-06 2025-09-12 上海医药集团股份有限公司 A spiro heterocyclic compound, preparation method and application thereof
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor
WO2025133948A1 (en) * 2023-12-21 2025-06-26 Pfizer Inc. Acetyl coa-carboxylase (acc) inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) * 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
JP2001516330A (en) * 1995-06-06 2001-09-25 メルク エンド カンパニー インコーポレーテッド Alpha 1a adrenergic receptor antagonist
AU2001289831A1 (en) * 2000-09-06 2002-03-22 Bayer Aktiengesellschaft Medicaments against viral infections
JPWO2004092179A1 (en) * 2003-04-14 2006-07-06 日本曹達株式会社 Spiro derivatives, production methods and antioxidants
JP2005119987A (en) * 2003-10-15 2005-05-12 Ajinomoto Co Inc Acylsulfonamide derivative
WO2006040329A1 (en) * 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
JP2008540395A (en) * 2005-05-03 2008-11-20 ファイザー・インク Amidoresorcinol compounds
MX2008000966A (en) * 2005-07-19 2008-03-26 Merck & Co Inc Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors.

Also Published As

Publication number Publication date
RS20090249A (en) 2010-06-30
CO6180424A2 (en) 2010-07-19
EP2097420A1 (en) 2009-09-09
AU2007326950B2 (en) 2010-10-14
CN101541809A (en) 2009-09-23
KR20090083956A (en) 2009-08-04
CA2670422C (en) 2011-09-06
AU2007326950A1 (en) 2008-06-05
SV2009003281A (en) 2010-08-17
CA2670422A1 (en) 2008-06-05
EA200900613A1 (en) 2009-10-30
MA30932B1 (en) 2009-11-02
ATE552262T1 (en) 2012-04-15
TN2009000204A1 (en) 2010-10-18
IL198779A0 (en) 2010-02-17
EP2097420B1 (en) 2012-04-04
NO20091889L (en) 2009-06-17
ECSP099371A (en) 2009-06-30
CR10831A (en) 2009-06-18
ZA200903268B (en) 2010-07-28
BRPI0721053A2 (en) 2014-07-29
US20090270435A1 (en) 2009-10-29
AP2009004880A0 (en) 2009-06-30
WO2008065508A1 (en) 2008-06-05
JP2010511035A (en) 2010-04-08

Similar Documents

Publication Publication Date Title
MX2009005604A (en) Spiroketone acetyl-coa carboxylase inhibitors.
WO2009144555A8 (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
PT1984357E (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
MX2009000884A (en) Pyridizinone derivatives.
MY162157A (en) Substituted indole mcl-1 inhibitors
UA94833C2 (en) Substituted bicyclolactams
WO2009155121A3 (en) Inhibitors of pi3 kinase
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
TW200621232A (en) Compounds for inflammation and immune-related uses
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MX2011012628A (en) Substituted aminopropionic derivatives as neprilysin inhibitors.
TW200722100A (en) A therapeutic agent for a β related disorders
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
WO2007019251A3 (en) Sphingosine kinase inhibitors and methods of their use
MX2009005691A (en) Inhibitors of diacylglycerol o-acylotransferase type 1 enzyme.
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
MX2007015863A (en) Sphingosine kinase inhibitors.
TW200517106A (en) Sustained release pharmaceutical compositions
TNSN08191A1 (en) Kinase inhibitors
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
MX2009004746A (en) 1,2,4-triazole derivatives as sigma receptor inhibitors.
TW200612958A (en) Substituted imidazole derivatives
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal